دورية أكاديمية
The Dose of Somatostatin Analogues during Pre-Surgical Treatment Is a Key Factor to Achieve Surgical Remission in Acromegaly
| العنوان: | The Dose of Somatostatin Analogues during Pre-Surgical Treatment Is a Key Factor to Achieve Surgical Remission in Acromegaly |
|---|---|
| المؤلفون: | Marta Araujo-Castro, Eider Pascual-Corrales, Héctor Pian, Ignacio Ruz-Caracuel, Alberto Acitores Cancela, Sara García Duque, Víctor Rodríguez Berrocal |
| المصدر: | Endocrines, Vol 2, Iss 23, Pp 241-250 (2021) |
| بيانات النشر: | MDPI AG |
| سنة النشر: | 2021 |
| المجموعة: | Directory of Open Access Journals: DOAJ Articles |
| مصطلحات موضوعية: | acromegaly, somatostatin analogues, presurgical treatment, surgical remission, Diseases of the endocrine glands. Clinical endocrinology, RC648-665 |
| الوصف: | Purpose: to determine whether pre-surgical treatment using long-acting somatostatin analogues (SSAs) may improve surgical outcomes in acromegaly. Methods: retrospective study of 48 patients with acromegaly operated by endoscopic transsphenoidal approach and for first time. Surgical remission was evaluated based on the 2010 criteria. Results: most patients, 83.3% ( n = 40), harbored macroadenomas and 31.3% ( n = 15) invasive pituitary adenomas. In this case, 14 patients were treated with lanreotide LAR and 6 with octreotide LAR, median monthly doses of 97.5 [range 60–120] and 20 [range 20–30] mg, respectively, for at least 3 months preoperatively. Presurgical variables were comparable between pre-treated and untreated patients ( p > 0.05). Surgical remission was more frequent in those pre-treated with monthly doses ≥90 mg of lanreotide or ≥30 mg of octreotide than in untreated or pre-treated with lower doses (OR = 4.64, p = 0.025). However, no differences were found between pre-treated and untreated patients when lower doses were included or between those treated for longer than 6 months compared to those untreated or pre-treated for shorter than 6 months. Similarly, no differences were found either in terms of surgical or endocrine complications (OR = 0.65, p = 0.570), independently of the doses and the duration of SSA treatment ( p > 0.05). Conclusions: the dose of SSAs is a key factor during pre-surgical treatment, since the beneficial effects in surgical remission were observed with monthly doses equal or higher than 90 mg of lanreotide and 30 mg of octreotide, but not with lower doses. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 2673-396X |
| العلاقة: | https://www.mdpi.com/2673-396X/2/3/23Test; https://doaj.org/toc/2673-396XTest; https://doaj.org/article/de5653b0c6e14cb8b225a23fe4e2127cTest |
| DOI: | 10.3390/endocrines2030023 |
| الإتاحة: | https://doi.org/10.3390/endocrines2030023Test https://doaj.org/article/de5653b0c6e14cb8b225a23fe4e2127cTest |
| رقم الانضمام: | edsbas.205FAFA6 |
| قاعدة البيانات: | BASE |
| تدمد: | 2673396X |
|---|---|
| DOI: | 10.3390/endocrines2030023 |